XT
RARE icon

XTX Topco’s Ultragenyx Pharmaceutical RARE Stock Holding History

XTX Topco’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Buy
38,521
+14,634
+61% +$363K 0.02% 1553
2026
Q1 		$500K Sell
23,887
-96,109
-80% -$2.16M 0.01% 2054
2025
Q4 		$2.76M Buy
119,996
+105,622
+735% +$3.47M 0.07% 380
2025
Q3 		$432K Sell
14,374
-22,846
-61% -$685K 0.02% 1185
2025
Q2 		$1.35M Buy
37,220
+5,440
+17% +$196K 0.06% 505
2025
Q1 		$1.15M Buy
31,780
+20,532
+183% +$854K 0.06% 484
2024
Q4 		$473K Sell
11,248
-3,381
-23% -$168K 0.04% 807
2024
Q3 		$813K Buy
14,629
+7,134
+95% +$363K 0.06% 524
2024
Q2 		$308K Sell
7,495
-5,726
-43% -$244K 0.03% 941
2024
Q1 		$617K Buy
13,221
+5,815
+79% +$274K 0.08% 363
2023
Q4 		$354K Sell
7,406
-5,613
-43% -$218K 0.08% 495
2023
Q3 		$464K Buy
13,019
+3,670
+39% +$145K 0.08% 449
2023
Q2 		$431K Sell
9,349
-1,820
-16% -$84.4K 0.08% 468
2023
Q1 		$448K Buy
11,169
+5,876
+111% +$252K 0.09% 364
2022
Q4 		$245K Buy
+5,293
New +$208K 0.05% 713

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

XTX Topco's RARE Position: Q2 2026 in Review

XTX Topco increased its Ultragenyx Pharmaceutical (RARE) stake by 61% in Q2 2026, buying an estimated $363K and bringing the position to 38,521 shares worth $1.29M. The position accounts for 0.02% of the portfolio, ranked #1553.

XTX Topco first reported a position in RARE in Q4 2022 and has held it in 15 quarters since. The position peaked at $2.76M in Q4 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • XTX Topco held 38,521 shares of Ultragenyx Pharmaceutical worth $1.29M as of Q2 2026.
  • XTX Topco bought 14,634 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $363K.
  • Ultragenyx Pharmaceutical made up 0.02% of XTX Topco's portfolio in Q2 2026, its #1553 holding.
  • XTX Topco first reported a position in Ultragenyx Pharmaceutical in Q4 2022 and has held it in 15 quarters since.
  • XTX Topco's Ultragenyx Pharmaceutical position peaked at $2.76M in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.